Tag: MRI

New Iron-based Contrast Agent for Cardiac Fibrosis Diagnoses and Treats

Photo by Mart Production on Pexels

Researchers have developed a new iron-based contrast agent for magnetic resonance imaging that can be used for both diagnosis and treatment. In a study conducted on lab-grown human heart tissue, it was demonstrated that the contrast agent accumulates in the fibrotic tissue, that its signal intensity on the MRI image increases with disease severity, and that it slows disease progression.

The Biomolecular Nanotechnology research group led by Ikerbasque research professor Aitziber L. Cortajarena developed the iron-based contrast agent. The study, led by Cortajarena and conducted in collaboration with Ana Villar’s group at the Institute of Biomedicine and Biotechnology of Cantabria (IBBTEC, UC-CSIC), has been published in Advanced Functional Materials. It paves the way for a possible alternative to gadolinium, the metal currently used in almost all contrast-enhanced MRI scans.

Cardiac fibrosis

Cardiac fibrosis is one of the main factors leading to heart failure, a disease that affects millions of people worldwide. There is currently no approved treatment specifically designed to slow down this condition. When the heart is damaged or under sustained strain (for example, after a heart attack or due to hypertension), a repair process begins, and the collagen production process is activated to repair and strengthen the tissue. However, this process often does not stop: the collagen continues to accumulate, the heart becomes stiff and finds it increasingly difficult to fill and pump the blood properly.

One of the techniques currently used for diagnosing fibrosis of the heart is MRI. In many cases, an intravenous contrast agent is administered to the patient, and is almost always based on gadolinium, which is retained in the damaged areas and lights them up. Although gadolinium works very well, it has various disadvantages. It is a metal that is foreign to the body. Its use is restricted in people with kidney failure, and it is known that small amounts of may be retained in different tissues for many years. This is especially concerning in patients who require repeated MRIs to monitor the progression of their disease, which is the case with cardiac fibrosis.

Iron atoms encapsulated in a custom-designed protein

For this reason, for many years researchers have sought to develop contrast agents based on iron, a metal that the body is familiar with and knows how to store and eliminate. However, there is a problem with existing iron-based contrast agents since, instead of illuminating the damaged area, they darken it, making it difficult to distinguish it in the images. Many of them have even been withdrawn from the market. The group led by Cortajarena, Scientific Director at CIC biomaGUNE, has been able to “overcome these problems by using designer proteins”, explains CIC biomaGUNE researcher Lydia Martínez Parra, lead author of the study.
Martínez adds, “the contrast agent consists of a specially designed protein that encapsulates and isolates minute clusters of iron atoms measuring approximately 1.4 nanometres (around 50 000 times thinner than a hair). It is also worth noting that this compound is safer for the body, is stable, releases very little iron and is of low toxicity to cells. Furthermore, it is easy and sustainable to manufacture, since it is produced in water, without toxic reagents or extreme conditions.”

A lab-grown fibrotic heart

The CIC biomaGUNE group has tested the efficacy of the contrast agent in cardiac tissue created with 3D tissue engineering using patients’ heart cells, developed by Ana Villar’s group (IBBTEC, UC-CSIC). These tissues replicate certain characteristics of cardiac fibrosis, such as the accumulation of collagen and increase in tissue stiffness, and enable new therapeutic strategies to be evaluated in more representative conditions than conventional cell cultures.

Thus, the research team has verified that the contrast agent moves towards and accumulates predominantly in the fibrotic tissue, that the signal on the MRI increases with the severity of the fibrosis, and that it slows its progression since it reduces the production and storage of collagen and prevents the tissue from becoming stiff. “That is, as well as indicating where the damage is, this material shows antifibrotic activity in the models studied”, says research professor Cortajarena. This is a ‘theranostic’ agent that offers diagnosis and treatment in the same material.”

Martínez points out that “this new compound enables the achievement of a contrast in magnetic resonance imaging comparable to that of gadolinium-based agents. It also retains this capacity in both magnetic fields commonly used in clinical practice and stronger magnetic fields used in preclinical research.” The compound formed by the iron atoms encapsulated by the protein make the tissue appear bright on the MRI.

The team behind the study affirms that “there’s still a way to go to reach the patient. For now, this new contrast agent has been tested in cells and human tissue in the laboratory. The next step will be to study it so that it can be used in clinical practice, to see how it is distributed and eliminated from the body and how it behaves on a real cardiac scanner. Our goal is that, in the future, patients with cardiac fibrosis, including those who cannot receive gadolinium, can have a safer imaging test that also forms part of their treatment.

Source: CIC biomaGUNE

Why MRI is Changing Prostate Cancer Diagnoses

Preparing a patient for a prostate MRI

As we approach Movember with a focus on men’s health, we talk to Dr Hein Els, a radiologist specialising in abdominal imaging at SCP Radiology and Dr Louw-Waldi Vlok, a urologist at Mediclinic Panorama, about why MRI has become such an important tool in detecting prostate cancer and guiding diagnosis.

It’s often not the man who notices something first. His partner may mention noticing he has been up three or four times a night. He’ll put it down to getting older or having a cup of tea too late in the evening. What happens next is usually a visit to your GP…

How common is prostate cancer in the first place?

“Prostate cancer is the top invasive cancer reported in men in South Africa and also one of the most treatable, when it’s caught early,” says Dr Vlok. “Knowing what to look out for and understanding how far diagnosis and treatment have come, can reduce the fear and uncertainty around the disease. Today’s imaging technology means men get answers faster, treatment only when necessary and fewer invasive procedures than they would have a decade ago.”

What are the symptoms of prostate cancer?

“It is very important to realise that in the early stages of prostate cancer the patient will often have no symptoms at all”, says Dr Vlok. “Some men may have symptoms of an enlarging prostate which can include:  Needing to urinate more often, particularly at night, a weak or interrupted urine flow and even an inability to urinate and difficulty starting or stopping urination.

As the disease progress and grows beyond the prostate the symptoms will increase:

  • Blood in urine or semen
  • Pain in the pelvis or lower back

Are there any unusual or less obvious signs?

“Yes,” says Dr Vlok, “and these are the ones men are least likely to connect to the prostate.” In more advanced cases, prostate cancer can cause:

•           Unexplained pain in the lower back, hips or pelvis

•           New or worsening erectile difficulties

•           Unexplained weight loss or persistent fatigue

•           Swelling in the legs or feet

‘These signs can point to the cancer having spread beyond the prostate, most often to the bones. They can also have entirely unrelated causes, so the sensible response is to get checked rather than to worry. Catching a change early is exactly what makes modern diagnosis so effective.

These symptoms don’t automatically mean cancer. An enlarged prostate or inflammation of the prostate is common with age and usually benign, but any of these changes are worth mentioning to your doctor.

How was prostate cancer diagnosed before MRI?

For decades, the standard path was a physical examination and a PSA blood test. In many cases this is still the standard workup. The test measures the amount of prostate-specific antigen (PSA) in your blood. PSA is a protein produced by both cancerous and noncancerous tissue in the prostate, a small gland that sits below the bladder in males. If either raised concern, a biopsy followed.

This approach had/has a real drawback: Without imaging to guide it, a biopsy could miss cancer that was there or flag concern in men who didn’t actually need treatment. The biopsy itself was usually systematic. A urologist took a set number of tissue samples from across the prostate using ultrasound guidance, without being able to see whether any specific area actually looked suspicious. It worked but was something of a blind search. Some cancers were missed simply because the needle didn’t pass through them, while other men went through an invasive procedure and a period of anxious waiting, for a result that turned out to be low risk or clear. If the result was clear and symptoms carried on, only then would an MRI be ordered.

How does MRI fit into prostate cancer diagnosis now?

“This reactive approach was certainly not ideal,” says Dr Els. The international standard has fundamentally changed and the sequence is different. After a raised PSA result, the patient is usually sent to radiology for a multiparametric MRI of the prostate, before any biopsy is considered”, says Dr Els.

“This is a detailed scan that maps the prostate and identifies areas that look suspicious,’ Dr Els explains. ‘It’s non-invasive: No incisions, just a detailed set of images generated using magnetic fields rather than radiation. We review the scan and score any area of concern, so the urologist has a clear picture of where and how likely, anything significant might be. If there’s a concerning lesion, a targeted, MRI-US fusion guided biopsy is performed.”

The major advantage is that many men with a clear or low-risk MRI avoid a biopsy altogether. When an area does need sampling, the biopsy can be targeted precisely, which means fewer samples, a more accurate result and a much shorter path to an answer.

This shift is supported by the PRECISION and MRI-FIRST trials and endorsed by the European Association of Urology and the American Urological Association.

What does the MRI tell the specialist?

‘Once the prostate is imaged, we don’t just report whether something looks suspicious but we give it a score, says Dr Els. ‘This is called PI-RADS, short for Prostate Imaging Reporting and Data System and it runs from 1 to 5. The number tells your doctor how likely it is that what’s showing on the scan is aggressive cancer and whether a biopsy is worth doing at all.’

  • Scores 1 and 2: Usually mean no dangerous cancer is seen. Your doctor may simply monitor you over time
  • Score 3: The scan cannot give a clear answer either way. Doctors will look at other information, such as your PSA blood test, before deciding on a biopsy
  • Scores 4 and 5: Mean a high chance of cancer and a biopsy is usually recommended

This shift, from a blind search to a targeted, image-led approach, is one of the most significant improvements in prostate cancer care in the last 15 years and it’s an area in which SCP Radiology has invested heavily to get right.

Prostate cancer, when found early, has excellent outcomes. The combination of a simple blood test and non-invasive, expert-led imaging means most men now get a clear, accurate picture of their prostate health with far less uncertainty than in the past.

‘Our radiologists work closely with urologists across the circle of care, to make sure every scan is read with the depth of experience this diagnosis deserves,’ explains Dr Els.

And, if you’re reading this because you’ve noticed a change in someone else, not yourself: Raising it is worth the slightly awkward conversation. It’s often exactly what starts the process early.

FAQs

Is a prostate MRI painful or invasive?

No. It uses magnetic fields and involves no incisions.

If my PI-RADS score is low, do I still need a biopsy?

Usually not. A low score, 1 or 2, generally means your doctor will monitor you over time, rather than proceed to biopsy.

How long does the process take, from a raised PSA result to an answer?

This varies because the MRI is done before any biopsy. Many men reach a clear answer or avoid a biopsy altogether, in far fewer steps than under the older approach.

Is prostate cancer treatable if caught early?

Yes. It’s one of the most treatable cancers in men when detected early, which is why regular check-ups matter, even in the absence of symptoms.

The Science and Challenge Behind Replacing MRI Machines

Moving a Magnetic Resonance Imaging (MRI) machine is not as simple as out with the old and in with the new. It is an engineering feat – part physics, part choreography. It is not just a machine, it is an entire system that needs structural support and specialised housing.

The MRI machine being hoisted into its new position.

Some Quite Interesting (QI) facts about moving an MRI machine

MRI machines are marvels of engineering, with their powerful magnets requiring precise handling and specialised support. The magnet, which is the heart of the MRI, can weigh several tonnes and must remain cold, often near absolute zero, maintained by liquid helium or other cooling methods.

‘When replacing an MRI machine, the process is carefully orchestrated, starting with meticulous planning and structural assessments,’ explains Tinus van Rooyen, Business Project Manager at SCP Radiology. The date of the move is carefully selected to coordinate the team of engineers, crane operators and logistics professionals.

‘It is far more complex than moving almost any other piece of hospital or healthcare equipment. Which is why,’ says van Rooyen, ‘removing our old MRI machine and replacing it is not quite ‘all in a day’s work’. And our practice is doing it across multiple sites over the coming months.’

The new MRI machines contain less than 1% of the scarce and non-renewable resource, helium, than that of a conventional MRI machine, improving operational efficiency and long-term sustainability. ‘The newer MRI systems use sealed magnets that, although having to be kept at a temperature of 4 Kelvin (-269.15° Celsius), require very little helium and no refilling over their lifetime’, explains van Rooyen. ‘The improvements in technology in the new machines also ensure improved image quality.’

What is an MRI machine?

MRI ready for its first patient.

The powerful magnetic field and radio waves create detailed images of the body, enabling radiologists to look at soft tissues like the brain, spine, joints and organs in extraordinary detail and without using any radiation. ‘Everything is controlled by advanced computer systems, which convert signals into detailed scans. If an MRI is listening for whispers from the body, a Faraday cage – using copper or aluminium – shields the room to ensure it’s completely silent, so these can be heard clearly.’

How heavy is an MRI machine?

Heavier than most people expect. A low helium MRI machine weighs in at around 3.3 tonnes (3 300kg) – about the weight of an elephant and is significantly less than the conventional machines. The magnet alone is about 60 000 times stronger than Earth’s magnetic field when it’s fully operational and can weigh several tonnes. It’s unsurprising that installing one is a major engineering exercise.

Why would an MRI machine be replaced – what is the usual lifespan of a machine?

The lifespan of an MRI is approximately 10 – 15 years. Replacing ageing equipment ensures access to the latest technology, including improved image quality and an enhanced patient experience. Machines can also reach End of Support (EOS). ‘This means manufacturers no longer support and maintain the unit and parts are unavailable,’ says van Rooyen. ‘It therefore becomes unreliable to keep it running. Patient care is paramount, as is minimising potential downtime and ensuring continuity of service.’

What happens when a machine is replaced?

The old one needs to be ramped down (gradually reducing the strength of the scanner’s main magnetic field to zero in a controlled way). It is then disconnected and removed.

Installation of new unit is basically a reverse of the ramping down process. Once the unit is in place, the magnet is cooled to a superconducting state, then ramped up by gradually increasing the electrical current in the magnet coils, causing the magnetic field to slowly rise. After the magnet has reached its specified strength, the magnetic field is then aligned to make it as uniform as possible, ahead of the unit being calibrated and tested.  The entire process can take up to eight weeks. Careful planning ensures continuity of service, with alternative arrangements in place where necessary.

What are the challenges and logistics during the move?

The MRI machine at the SCP Radiology branch at Mediclinic Louis Leipoldt is housed on the first floor. The challenges included building a platform outside the building, moving and lifting the units, with the external wall being removed to create access. The equipment manufacturers oversee the installation but it required a team of riggers to assist with taking out the old unit, then lifting and installing the new unit off the delivery vehicle using a crane, onto a platform and then into the building. Additional contractors are responsible for preparing the room – this includes copper cladding, drywalling, reinforced flooring (if required), painting, joinery, etc.

‘The installation of each MRI unit is unique and depends on a number of factors. In the case of this new one at Louis Leipoldt, we had to partly close off a section of the road for the unloading and lifting. Getting the MRI into the building is a display in itself. Powerful cranes are used to lift the machine, hoisting it through a specially constructed opening. Every step demands precision to avoid damaging the magnet or the building and the installation requires coordinated planning with multiple stakeholders to ensure that the project is executed safely and efficiently,’ explains Heinie Matthysen, SCP’s Facilities Manager.

‘Everything is planned in minute detail by our facilities manager,’ says van Rooyen, ‘however, we also have to factor in the Cape Town weather that has a mind of its own’.

So, you can’t install an MRI in any room?

No, there are key requirements for the machine to work effectively and safely. These include a Faraday cage, which serves two purposes: To keep external radiofrequency signals out (so that they do not interfere with the MRI) and keep MRI radiofrequency signals in (to prevent these signals from affecting other equipment).

Copper (which this cage is made of, although aluminium can also be used) is an excellent conductor of electricity, highly effective at blocking electromagnetic waves, durable and relatively easy to install as sheets or mesh.

‘The room is engineered around the scanner. Without shielding and safety systems, the images would be unreliable and the risks much higher, ‘says van Rooyen.

The three facilities having their MRI machines replaced are:

  • SCP Radiology Louis Leipoldt (at Mediclinic Louis Leipoldt in Bellville): 16 April to 3 June
  • SCP Radiology Vredenburg (at Life West Coast Private Hospital in Vredenburg):

27 June to 3 August

  • SCP Radiology Worcester (at Mediclinic Worcester in Worcester): Timelines TBC

Is it Safe to Have an MRI After Hip or Knee Replacement Surgery?

A patient with a knee replacement undergoing an MRI where modern technology reduces the distortions in the images.

It is a common concern for patients that metal implants, such as hip or knee replacements, may prevent them from having an MRI scan. In most cases, this is not true. Patients with modern joint replacements can safely undergo MRI, depending on the materials used in the implant. It is important to inform the radiology team about the implant before your scan.

Dr Jean de Villiers, a radiologist and director of SCP Radiology, answers some of the questions most frequently asked by patients, specifically around the process from referral to reporting in radiology imaging.

What is Magnetic Resonance Imaging (MRI)?

MRI is a non‑invasive imaging technique that uses powerful magnets and radio waves to create detailed images of the body’s internal structures. Unlike X‑rays or CT scans, MRI does not involve ionising radiation and is used extensively to diagnose a wide range of conditions.

Because MRI uses strong magnetic fields, many patients ask whether it is safe to have an MRI after a hip or knee replacement.

Can you have an MRI after a hip or knee replacement?

Yes, you can have an MRI scan on other parts of the body, as well as on the knee or hip where the implant is. Although some older MRI scanners may not be compatible with certain prostheses, the vast majority of MRI equipment in use today is safe and compatible with modern hip and knee implants.

How safe is MRI if the implant is made of metal?

Most implants are made from titanium or cobalt‑chromium alloys. Although these materials are metallic, they are not significantly affected by the magnetic field of an MRI scanner, nor do they heat up during the scan. Many implants also contain hard plastic components, all of which are designed to be compatible with MRI scanners. They are not attracted to the powerful magnet in the same way as older or highly magnetic materials.

Dr de Villiers explains, “The vast majority of joint replacements used today are MRI‑safe. The key is that we know about them in advance, so we can adjust the scan if needed.”

What is the main challenge with MRI and an implant?

The main challenge is image quality. Metal can sometimes cause image distortion, known as artefact, on MRI images. This may make it more difficult to assess structures close to the implant. However, modern MRI techniques have improved significantly and can often minimise these effects, allowing radiologists to assess surrounding tissues such as muscles and ligaments, and to detect complications such as infection or loosening. MRI is often the best imaging method for evaluating pain or complications after joint replacement surgery.

What happens if MRI does not produce clear diagnostic images?

In some cases, alternative imaging techniques such as CT or ultrasound may be recommended, depending on the clinical question. However, MRI remains safe and highly valuable for many patients with joint prostheses.

Are there implants that prevent you from having an MRI?

Certain implants and devices may be unsafe or require special precautions during MRI, including:

  • Implanted pacemakers
  • Intracranial aneurysm clips
  • Cochlear implants
  • Certain prosthetic devices
  • Implanted drug‑infusion pumps
  • Neurostimulators
  • Bone‑growth stimulators
  • Any other iron‑based metal implants

MRI is also contraindicated in the presence of some internal metallic objects such as bullets or shrapnel, as well as certain surgical clips, pins, plates, screws, metal sutures or wire mesh.

Having a hip or knee replacement does not automatically exclude you from having an MRI scan. With modern implants and appropriate planning, MRI is both a safe and important diagnostic tool. As technology continues to evolve, future developments are expected to further enhance MRI compatibility with hip and knee implants, making it an even more reliable tool for ongoing patient care.

It is crucial for patients to inform their healthcare providers about their joint replacement before undergoing an MRI. This allows the medical team to adjust the MRI settings and take appropriate precautions to ensure both safety and diagnostic accuracy.

New Antenna Upgrade Boosts MRI Image Quality

Photo by Mart Production on Pexels

Magnetic resonance imaging (MRI) is one of medicine’s most powerful diagnostic tools. But certain tissues deep inside the body – including brain regions and delicate structures of the eye and orbit that are of particular relevance for ophthalmology – are difficult to image clearly. The problem is not the scanner itself, but the hardware that sends and receives radio signals. 

Now, researchers at the Max Delbrück Center have developed an advanced materials-based MRI antenna that overcomes these limitations – delivering enhanced images more quickly and that can be used in existing MRI machines. The research, led by Nandita Saha, a doctoral student in the Experimental Ultrahigh Field Magnetic Resonance lab of Professor Thoralf Niendorf, was published in Advanced Materials.

Niendorf and his team worked closely with researchers at Rostock University Medical Center, combining expertise in MRI physics with clinical ophthalmology and translational imaging. The Rostock team is also supporting clinical validation of the technology.

“By using concepts from metamaterials, we were able to guide radiofrequency fields more efficiently and demonstrate how advanced physics can directly improve medical imaging,” says Niendorf, senior author of the paper. “This work shows a pathway toward faster, clearer MRI scans that could benefit patients in many clinical areas.” 

Rethinking MRI hardware with metamaterials

MRI works by sending radiofrequency (RF) signals into the body and detecting how tissues respond inside a strong magnetic field. The stronger the signal response, the better the image. Conventional MRI antennas – also called RF coils – often struggle to collect enough signal from deep or anatomically complex regions. This leads to images that lack detail and prolongs scan times.

The research team addressed this bottleneck by integrating metamaterials directly into the MRI antenna. Metamaterials are engineered structures that interact with electromagnetic waves in ways not found in natural materials. The engineered RF antenna increases signal strength from targeted tissues, improves spatial resolution and image sharpness and enables faster data acquisition. Crucially, the antenna fits into existing MRI systems, avoiding the need for new infrastructure. The team validated the technology by imaging the eye and orbit region in a group of volunteers at 7.0 Tesla.

MRI image of an eye, the eye socket and the brain.
© AG Niendorf, Max Delbrück Center

“Our research demonstrates clear relevance for ophthalmological applications as it can facilitate anatomically detailed, high-spatial resolution MRI of the eye,” says Professor Oliver Stachs, a co-author of the paper at University Medicine Rostock. “It offers the potential to open a window into the eye and into (patho)physiological processes that in the past have been largely inaccessible.” 

“Our goal was to rethink MRI hardware from the modern physics of antenna design,” adds Saha. This technology can also be tuned to protect sensitive areas of the body during MRI, for example, to reduce unwanted heating around medical implants, she adds. It could also be used to focus RF energy more effectively for MRI guided therapies for various cancer treatments, such as gentle heating of tumors (hyperthermia) or thermal ablation of tissue. 

Better diagnostics

For patients, MRI scans can be uncomfortable and time-consuming – even more so when images need to be repeated because important details are hard to see. Faster scans mean patients spend less time inside scanners. Clearer images mean doctors can make diagnoses with greater confidence. And because the new antenna is lightweight and compact, it can also be designed to better fit specific parts of the body, improving comfort even further.

The technology could also be adapted to support MRI systems running at magnetic field strengths lower or higher than 7.0T, to image target anatomy other than the eye, orbit or the brain or to track metabolism or drug movement inside the body, says Niendorf. Special MRI scans that use other atoms, such as sodium or fluorine, could also benefit from this technology by producing clearer signals and better images, he adds. 

“Innovations in imaging hardware have the potential to transform diagnostics, and this study is an important step toward next-generation MRI technology,” says Dr Ebba Beller, a co-author of the paper at Rostock University Medical Center.

The researchers are already planning larger studies at multiple hospitals and adapting the design for other organs, such as the heart and kidneys. The collaboration will continue to be strengthened by long-standing reciprocal visiting scientist appointments of Stachs and Niendorf. 

Source: Max Delbrück Center for Molecular Medicine

Study Shows Low-Field MRI Is Feasible for Breast Screening

Mass General Brigham’s evaluation of low-field MRI performance lays potential groundwork for this technology to be a lower-cost, accessible option for breast imaging

Photo by National Cancer Institute on Unsplash

Researchers at Mass General Brigham have demonstrated the technical feasibility of using ultra-low field (ULF) magnetic resonance imaging (MRI) for breast imaging. With further refinement and evaluation, the technology could offer an alternative to existing breast cancer screening methods and may reduce barriers to screening. Results are published in Scientific Reports.

“These results are a very encouraging proof of principle, though larger studies are needed to establish diagnostic performance,” said project principal investigator and co-senior author Matthew Rosen, PhD, an associate professor of Radiology and director of the Low Field MRI laboratory in the Athinoula A. Martinos Center for Biomedical Imaging in the Mass General Brigham Department of Radiology. “They motivate our continued pursuit of safe, comfortable, lower-cost screening approaches that can expand access for patients.”

Current U.S. guidelines recommend screening mammography for women aged 40 to 74 years. Unlike mammography, ULF MRI doesn’t require breast compression, which many patients find uncomfortable. Another benefit of ULF MRI is that it doesn’t use ionizing radiation.

While higher risk patients may receive MRI screening for breast cancer, standard MRI machines are not used in routine breast cancer screening because they are expensive and not widely available. ULF MRI systems cost less than 5% of the price of standard MRI systems and have lower long-term operating costs.

In this study, ULF MRI scans were performed on 14 participants, including 11 women with no history of breast cancer, two women with a prior breast cancer diagnosis, and one woman with a benign mass.

When interpreting the ULF MRI scans, three radiologists could reliably identify essential breast features and distinguish fibroglandular tissue from adipose tissue. The authors note that discrepancies were likely related to the novelty of ULF MRI and may be reduced with additional training and experience.

“This early evidence suggests that ULF MRI can detect essential breast features and some abnormalities without radiation or injected contrast,” said co-first author Neha Koonjoo, PhD, an investigator at the Martinos Center. “These findings point to the potential for ULF MRI as an option that could complement existing screening tools in the future.”

“Even at very low magnetic field, the radiology team was able to make observations about the breast,” said co-principal investigator and co-senior author Kathryn E. Keenan, PhD, from the US National Institute of Standards and Technology. “We attempted this study in hopes that the breast features would be visible, but you don’t always have success. We’re very motivated by this study to continue our work on ultra-low-field MRI for breast screening.”

The researchers note that further study is needed to determine the diagnostic accuracy of ULF MRI for breast cancer screening, including studies in larger cohorts that include patients with benign and malignant lesions. They also emphasize that further refinements in ULF MRI technology are needed to meet clinical resolution standards for breast cancer screening.

“These results will guide the next engineering steps to improve image quality and enable a more comfortable exam and help bring screening to more settings and more patients,” said co-first author Sheng Shen, PhD, of the Martinos Center for Biomedical Imaging.

Source: Mass General Brigham

Doctors Complain About Choice of Equipment at Gauteng Hospital as Thousands Await Cancer Scans

Concern about decision to buy Chinese MRI machine from local company instead of one from Philips

Credit: Pixabay CC0

By Chris Bateman and Raymond Joseph

As thousands of cancer patients wait months for diagnostic scans, senior clinicians at Charlotte Maxeke Academic Hospital have questioned a decision by the Gauteng Health Department to override their choice of MRI machine.

In a letter to Gauteng Health Department’s acting chief financial officer, the head of supply chain management at the hospital, Solly Mokgoko, expressed a concern that a recommendation by the head of radiology and the acting clinical director to buy a Philips scanner had been overridden by the Gauteng health department’s central office. The letter is dated 31 October 2025.

Mokgoko said the doctors had preferred the Philips MRI scanner – at a cost of about R27.4-million – on the grounds of “technological advancement, operational sustainability, and clinical research potential”.

However, the department had chosen a machine from Mamello Clinical Solutions at R38.5-million, they said. The room in which the machine will be installed is currently being prepared.

The letter said the Philips unit’s cost “offers reduced lifecycle expenditure due to minimal helium dependency and extended operational uptime”. The Philips scanner used low-maintenance technology, “requiring minimal or no helium top-ups, thereby reducing lifecycle costs and mitigating downtime risks”.

The Mamello-proposed model, by contrast, “relies on traditional cryogenic technology, which entails higher running costs and environmental exposure”, they said.

They said the decision is inconsistent with value-for-money principles set out in the Public Finance Management Act (PFMA) and Treasury regulations.

The purchase of a Chinese MRI scanner from Mamello is part of a R304-million roll-out of eight scanners across Gauteng public hospitals, in which roughly R190-million has been awarded to Mamello Clinical Solutions (five machines) and the remainder to Philips SA.

The Gauteng Department of Health rejected any suggestion of irregularity, saying the purchase was made under a lawful, competitively awarded contract and that both suppliers met the required technical standards.

In this case, the original procurement contract was drawn up by the Limpopo Health Department, with the Gauteng department piggybacking on it.

Clinicians at Charlotte Maxeke who spoke to GroundUp say the procurement shift occurred without adequate consultation and against explicit technical recommendations — allegations the department disputes.

Approximately 2,600 oncology patients are awaiting MRI scans at Charlotte Maxeke alone, with outpatient bookings extending to December 2026. Similar waiting lists exist at Chris Hani Baragwanath Academic Hospital.

The letter said that besides the external patient scans waiting list, there are over 50 inpatients awaiting scans.

One department head said: “How can the hospital order an MRI that’s over R10-million more expensive in an environment where it can’t even provide decent food, [and where there is] widespread cost-cutting and a dire shortage of doctors?” Late last year, the hospital made headlines for shortages of adequate patient meals.

Mamello Clinical Solutions, a private company based in Polokwane, was established in December 2014, trading as Mamello Development until 2019 when it changed its name. Robert Makhubedu, its sole director, was appointed in June 2023 after two previous directors resigned, according to official company registration records.

Makhubedu previously worked as chief radiographer at Charlotte Maxeke Hospital in the early 1990s, then spent more than two decades as director of business development at Tecmed, before joining Mamello Clinical Solutions.

A Gauteng Health Department spokesperson “categorically” denied any irregular, inflated or non-compliant procurement.

He said the MRI acquisitions had been made under a lawful, competitively advertised contract which had been evaluated in line with constitutional, PFMA and Treasury requirements.

Philips Healthcare and Mamello Clinical Solutions had both met minimum safety, functional and performance specifications, he said.

While acknowledging that Charlotte Maxeke clinicians preferred the Philips MRI, the spokesperson said procurement decisions could not be driven by “brand preference or proprietary technology.” He said over the life of the machine the price difference between the two was about R1.07-million, not R11.1-million.

Treasury rules, he said, did not permit sole-supplier selection where multiple bidders meet approved specifications. Multi-supplier models were standard public-sector practice.

Makhubedu pointed out that the tender had not called for a “helium-free” scanner. He attributed the doctors’ complaints to a combination of “brand bias” and hostility towards emerging black-owned companies, compared to multinationals.

“Some black companies awarded these contracts in the past could not relate to the business and clinical profile of the projects,” he said. “The legacy of that is that you have to prove yourself all the time.”

Makhubedu said that provinces tried to strike a procurement balance between emerging and established companies. He said his scanner was in fact R300,000 cheaper than the Philips machine over the life of the machine, and Mamello was capturing market share because of scanner quality and price.

“We believe we were fairly, legally and transparently awarded the contract. And we were cheaper.”

Republished from GroundUp under a Creative Commons Licence.

Read the original article.

Diagnostic Breast MRI may be Unnecessary for Some Patients with Early-stage Breast Cancer

Adding breast magnetic resonance imaging (MRI) to a diagnostic mammogram did not reduce five-year cancer recurrence rates for patients with stage I/II hormone receptor (HR)-negative breast cancer, according to researchers at The University of Texas MD Anderson Cancer Center. 

The Phase III Alliance A011104/ACRIN6694 trial found that five-year locoregional recurrence rates were 6.8% in patients who received an MRI as part of a diagnostic work-up and 4.3% in those who did not. These data were presented today at the San Antonio Breast Cancer Symposium (SABCS) by principal investigator Isabelle Bedrosian, MD, professor of Breast Surgical Oncology (Abstract GS2-07).

“We have long assumed that finding more breast cancer on an MRI and removing it with surgery would help lower the chance of a patient’s cancer coming back,” Bedrosian said. “When you look at our findings alongside earlier trials, the message is clear: adding MRI before surgery doesn’t improve results for patients – and may not have to be used as a standard part of the diagnostic process.”

No additional MRI benefit in this group

The trial enrolled 319 patients between 2014 and 2018 with newly diagnosed stage I or II HR-negative breast cancer. These patients were eligible for lumpectomy and did not have germline BRCA1/2 mutations, bilateral breast cancer or a history of prior breast cancer. All patients had undergone diagnostic mammography with or without ultrasound prior to trial enrolment.  Patients were randomly assigned to undergo additional imaging by breast MRI (161 patients) or to receive no further imaging (158 patients).

Not only did breast MRI not impact five-year recurrence rates, but there were also not significant differences between groups for five-year distant recurrence-free survival nor overall survival. 

A small subset of patients with tumour subtypes (HR- HER2+ and HR-HER2-) and those over the age of 50 at diagnosis also showed no benefit to MRI.

Pre-op MRI not finding anything important

Breast MRI is a common part of the diagnostic evaluation because it can reveal cancer that mammography might not detect. However, the evidence that it improves surgical outcomes for patients has been limited.

“We believe the reason MRI did not reduce recurrence rates may be twofold,” Bedrosian said. “It is possible that MRI didn’t uncover many lesions that mammography hadn’t already found, or perhaps identifying and surgically removing those additional lesions was not important to reducing risk of the cancer coming back. It’s possible that in the group that did not receive MRI, radiation and chemotherapy effectively treated the occult areas of disease”. 

Experts are now analysing how often breast MRI identified additional lesions in the trial population to better understand why breast MRI did not impact oncologic outcomes.

Study limitations 

Limitations included that most patients involved in the trial had breast cancer that hadn’t spread to their lymph nodes, which may partly explain why recurrence rates were low overall. Despite being open to women of all ages, the study enrolled mostly older women who may have been less likely to benefit from breast MRI. 

Study Highlights the Limits of AI in Heart Care

Human heart. Credit: Scientific Animations CC4.0

There are limits in applying AI to images of the heart, a new study from the Smidt Heart Institute at Cedars-Sinai reveals. The findings were published in the Journal of the American Society of Echocardiography.

Investigators trained multiple artificial intelligence models to read images from echocardiograms, a type of ultrasound test that evaluates the structure and function of the heart. Their goal was to determine whether AI could use these images to calculate measurements like inflammation and scarring that are normally obtained through another, more costly test called cardiac magnetic resonance imaging (CMRI). By examining findings from 1453 patients who had undergone both tests, they found the AI models could not accomplish this task.

“As compared to echocardiograms, cardiac MRI machines are expensive and not available for many patients, especially those in rural areas, so we had hoped that AI could reduce the need for it,” said Alan Kwan, MD, assistant professor in the Department of Cardiology in the Smidt Heart Institute at Cedars-Sinai and co-senior author of the study. “Our results showed the limited powers of AI in this area.”

Source: Cedars-Sinai Medical Center

New Method Noninvasively Assesses Achilles Tendon in Dancers

Photo by Nihal Demirci on Unsplash

A study in the Journal of Orthopaedic Research uses a noninvasive, nonradioactive imaging-based method to measure the structure and function of the Achilles tendon in professional ballet dancers. The method could potentially be developed to help prevent injuries and improve rehabilitation efforts in athletes, as well as in the general public.

The study involved what is called multi-echo ultrashort echo time (UTE) magnetic resonance imaging (MRI) to assess collagen and other components of the Achilles tendon. These structural UTE MRI assessments were combined with functional assessments of the Achilles tendon based on sheer wave elastography (SWE) ultrasound, which measures tendon stiffness.

Professional dancers tended to have more tendon stiffness compared with non-dancers, consistent with prior observations of a training effect from repeated loading with exercise. UTE MRI measures corresponded with the degree of stiffness from SWE ultrasound.

“These findings highlight the potential of integrating UTE and SWE imaging to investigate tendon structure‐function relationships and adaptations to mechanical loading,” the authors write. “Enhanced structure‐function assessment of tendon health and injury status could improve rehabilitation protocols or injury prevention strategies for athletes, including professional dancers.”

Source: Wiley